Save
Subperiosteal versus subdural drain after burr-hole drainage in patients with chronic subdural hematoma under platelet inhibitors and/or anticoagulants: a subanalysis of the cSDH-Drain RCT
EANS Academy. Kamenova M. Sep 27, 2019; 275956; EP05056
Dr. Maria Kamenova
Dr. Maria Kamenova

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy


Abstract
Discussion Forum (0)
Rate & Comment (0)
Background: The chronic subdural hematoma (cSDH)-Drain trial compared recurrence rates und clinical outcome associated with the use of subperiosteal drain (SPD) and subdural drain (SDD) after burr-hole drainage for cSDH. This subgroup analysis, of patients treated with platelet inhibitor or anticoagulants, aimed to determine whether one drain type is preferable in this sub-group of cSDH patients.
Methods: This subanalysis included 220 patients from the preceding cSDH-Drain trial. For patients treated with platelet inhibitor or anticoagulantsthe associations between the drain type and recurrence rates, mortality, as well as clinical outcome at 6 weeks and 12 months follow-up were analyzed using a logistic regression analysis model. Additionally, recurrence rates, clinical outcome, and mortality were assessed for each platelet inhibitor or anticoagulant type separately.
Results: The insertion of SPD was associated with lower recurrence rates (7.35%) compared to SDD (13.85%) in patients treated with platelet inhibitor or anticoagulants (OR 0.44, 95% CI 0.06 - 2.78, p=0.39). Outcome measurements and mortality did not differ significantly between both groups at 6 weeks and 12 months follow up. In addition, there was no statistically significant association between drain type and recurrence rate or mortality when comparing data for each platelet inhibitor or anticoagulanttype.
Conclusion: In patients treated with platelet inhibitor or anticoagulants, the insertion of SPD after burr-hole drainage of cSDH leads to lower recurrence rates and similar mortality rates and outcome at 6 weeks and 12 months follow up compared to SDD. These findings suggest that SPD may be favorable in patients treated with platelet inhibitor or anticoagulants.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings